Skip to main content
. 2011 Dec 20;106(3):508–516. doi: 10.1038/bjc.2011.545

Figure 2.

Figure 2

PFS and OS for patients without and with CTCs. (A) Progression-free survival of patients without CTCs vs those with CTCs using the CellSearch platform. Median survival (days) 140 vs 94 hazard ratio 0.63. P=0.13 (log rank). (B) Overall survival of patients without CTCs vs those with CTCs using the CellSearch platform. Median survival (days) 164 vs 127 hazard ratio 0.7. P=0.26 (log rank).